Jinming Gao, PhD, UT Southwestern Medical Center, Dallas, TX, reveals that extensive animal studies in tumor-bearing mice, investigating the encapsulated micelle formulation ONM-405, have shown an increase in the therapeutic window of over 100-fold. Very little immune-related toxicity was seen in the animal studies using micelle encapsulated IL-2Fc. T cells and NK cells were successfully activated in the tumor microenvironment, achieving anti-tumor efficacy in both MC38 colorectal cancer and B16-F10 melanoma tumor models. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
